CAU
HAE icon

Caxton Associates (UK)’s Haemonetics HAE Stock Holding History

Caxton Associates (UK)’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$257K Buy
+3,426
New +$220K ﹤0.01% 663
2025
Q2 		– Sell
-3,397
Closed -$216K – 774
2025
Q1 		$216K Buy
+3,397
New +$231K 0.01% 692

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caxton Associates (UK)'s HAE Position: Q2 2026 in Review

Caxton Associates (UK) opened a new position in Haemonetics (HAE) in Q2 2026: 3,426 shares worth $257K. The stake represents ﹤0.01% of the portfolio and ranks #663 among its holdings. This is a return to the name: Caxton Associates (UK) previously reported a position in HAE as recently as Q1 2025.

Caxton Associates (UK) first reported a position in HAE in Q1 2025 and has held it in 2 quarters since. 330 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Caxton Associates (UK) held 3,426 shares of Haemonetics worth $257K as of Q2 2026.
  • Haemonetics was a new Caxton Associates (UK) position in Q2 2026.
  • Haemonetics made up ﹤0.01% of Caxton Associates (UK)'s portfolio in Q2 2026, its #663 holding.
  • Caxton Associates (UK) first reported a position in Haemonetics in Q1 2025 and has held it in 2 quarters since.
  • 330 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.